Nutriband Inc. - Warrant (OQ:NTRBW)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Jun 03, 2024 07:00 am ET

Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year

ORLANDO, FL / ACCESSWIRE / June 3, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today reported Q1 revenues of $408,532 emphasizing its focus on expanding the company's Kinesiology Tape manufacturing services through its Pocono Pharma subsidiary. The Company has been focused on using penetration pricing to gain a foothold with some of the industry's largest brands and License holders such as KT Tape and Fit For Life Group, who hold licenses for major international brands such as Reebok, Adidas and New Balance.

May 21, 2024 07:00 am ET

Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on May 30

ORLANDO, FL / ACCESSWIRE / May 21, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical's and technology, is pleased to invite investors to a webinar on May 30, 2024, at 4:15 p.m. ET.

May 16, 2024 07:00 am ET

Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors

The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placement

Apr 24, 2024 07:00 am ET

Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission

Private Placement of $8.4 million has closed and will fund the commercial development of lead product AVERSA Fentanyl to NDA filing

Apr 23, 2024 07:00 am ET

Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group

ORLANDO, FL / ACCESSWIRE / April 23, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that following its engagement by Fit For Life Group (FFL), a major brand license holder, on April 19, 2024, the companies fully executed an exclusive Supplier agreement for FFL's new product launch under one of their top brands. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer.

Apr 19, 2024 07:00 am ET

Nutriband Inc. Announces $8.4M Private Placement

Nutriband is targeting a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025

Apr 01, 2024 07:00 am ET

Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance

ORLANDO, FL / ACCESSWIRE / April 1, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pharmaceutical company with a specific focus on transdermal technologies, today announces it has been engaged by and received a first order from Fit For Life Group (FFL), a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer.

Mar 27, 2024 05:50 am ET

Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch

NDA will be primarily based on a single Phase 1 human abuse potential clinical study with no Phase 2 or 3 clinical trials needed prior to submission.

Mar 25, 2024 07:00 am ET

Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting

Data highlights the incidence of abuse and accidental pediatric exposure of transdermal patches containing opioid and stimulant drugs

Mar 04, 2024 07:00 am ET

Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annu

ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that data on the incidence of transdermal patch abuse and accidental pediatric exposure will be presented at the 2024 American Academy of Pain Medicine (AAPM) Annual Meeting to be held in Scottsdale, Arizona March 7-10, 2024. The company engaged Rocky Mountain Poison & Drug Safety (RMPDS), a division of Denver Health and Hospital Authority, Denver, Colorado to determine the incidence

Jan 29, 2024 07:00 am ET

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st.

Jan 26, 2024 07:00 am ET

Nutriband CEO Publishes Letter to Shareholders

ORLANDO, FL / ACCESSWIRE / January 26, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and targets through 2023 and the potential outlook for 2024. The full text of the letter is below.

Jan 05, 2024 09:15 am ET

Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch

ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has signed a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with their partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products. Under this agreement, Kindeva will perform commercial manufacturing process development and manufacture clinical supplie

Nov 28, 2023 07:00 am ET

Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling

ORLANDO, FL / ACCESSWIRE / November 28, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its new Heating and Cooling Kinesiology Tape as part of its Active Intelligence (AI Tape) Brand portfolio. AI Tape Heating and Cooling provides all of the stretch, support, and benefits of traditional kinesiology tape, plus pain-relieving ingredients that provide both heating and cooling sensation for the temporary relief of minor aches and pains of muscles and joints.

Nov 08, 2023 07:00 am ET

Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape

ORLANDO, FL / ACCESSWIRE / November 8, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has signed a supplier agreement with market leading kinesiology tape company, KT Tape. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer for a new line of specialized KT tape.

Oct 11, 2023 08:00 am ET

Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm

ORLANDO, FL / ACCESSWIRE / October 11, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has completed the market assessment and commercialization strategy for AVERSA™ Buprenorphine, an abuse deterrent buprenorphine transdermal system.

Sep 20, 2023 07:30 am ET

Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology

Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology

Sep 12, 2023 07:00 am ET

Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023

Nominations recognize innovative development of AVERSA™ abuse-deterrent transdermal technology

Sep 11, 2023 07:00 am ET

Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

ORLANDO, FL / ACCESSWIRE / September 11, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the second quarter ended July 31, 2023.

Aug 30, 2023 08:00 am ET

Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador

AI Tape has potential to tap into the $236 million Elastic Therapeutic Tape market

Jul 27, 2023 08:30 am ET

Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings

ORLANDO, FL / ACCESSWIRE / July 27, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its consumer sports recovery tape brand, Active Intelligence AI Tape ("AI Tape"), with products now available for purchase on Amazon and Activeintell.com.

Jul 14, 2023 09:20 am ET

Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission

Company targeting FDA submission in the first half of 2024

Jun 23, 2023 07:00 am ET

Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology

ORLANDO, FL / ACCESSWIRE / June 23, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on June 15, 2023 for patent application 17/568,999, "Abuse and Misuse Deterrent Transdermal Systems" which covers its Aversa™ abuse deterrent technology. The receipt of a Notice of Allowance means that the USPTO is expected to issue a U.S. patent for this application after administrative processes have been compl

May 10, 2023 08:00 am ET

Nutriband to Attend 2023 BIO International Convention

ORLANDO, FL / ACCESSWIRE / May 10, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it will be attending the Biotechnology Innovation Organization (BIO) International Convention taking place June 5-8, 2023, at the Boston Convention & Exhibition Center, in Boston, Massachusetts, USA. The BIO Convention is the premier life sciences networking conference in the world, bringing together leaders, innovators and investors from the pharmaceutical, biotech and medical device industries.

Apr 27, 2023 08:00 am ET

Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023

ORLANDO, FL / ACCESSWIRE / April 27, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the fiscal year ended January 31, 2023.

Apr 19, 2023 07:00 am ET

Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023

ORLANDO, FL / ACCESSWIRE / April 19, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the development of innovative transdermal solutions, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 08:30 AM (Local Time -PST). Company CEO, Gareth Sheridan will be hosting the presentation and answering questions at the conclusion.

Apr 04, 2023 07:00 am ET

Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development

ORLANDO, FL / ACCESSWIRE / April 4, 2023 / Nutriband Inc.("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) with Kindeva Drug Delivery ("Kindeva") have selected the target AVERSA™ formulation to take forward into commercial scale manufacturing process development for the Company's patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal abuse deterrent technology which can be manufactured using standard commercial transdermal manufacturing processes and is c

Mar 28, 2023 08:00 am ET

Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology

ORLANDO, FL / ACCESSWIRE / March 28, 2023 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) has entered into a three-year $2,000,000 Credit Line facility to provide financing through the FDA approval process into commercial scale manufacturing for the Company's patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal abuse deterrent technology.

Mar 08, 2023 08:00 am ET

Nutriband Inc Joins Webull Corporate Communications Service Platform

ORLANDO, FL / ACCESSWIRE / March 8, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that it has joined Webull's Corporate Communications Service Platform, which will provide Nutriband with a comprehensive suite of investor relations and corporate communications solutions. This will enable Nutriband to enhance its corporate communications efforts, expand its investor outreach, and increase its visibility among potential investors.

Mar 02, 2023 08:00 am ET

Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert Committee

ORLANDO, FL / ACCESSWIRE / March 2, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that Alan Smith, Ph.D., Chief Operating Officer (COO), Nutriband, and President of its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has been selected for the FDA's Center for Research on Complex Generics Stakeholder Expert Committee on Adhesion Testing for Transdermal/Topical Delivery Systems.

Feb 15, 2023 06:00 am ET

Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador's Health Register

ORLANDO, FL / ACCESSWIRE / February 15, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its has completed the requirements to file its application with Ecuador's Health Register (Registro Sanitar Ecuador) to permit the distribution of certain medical devices and cosmetic products in South America.

Jan 24, 2023 06:00 am ET

Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference

ORLANDO, FL / ACCESSWIRE / January 24, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, today announced details of the Company's participation at the 2023 Transdermal and Microneedle Conference taking place January 23-24, 2023, at the Copthorne Tara Hotel, London, United Kingdom.

Jan 05, 2023 06:00 am ET

Nutriband Inc. Commences Trading on Upstream Under NTRB

Nutriband among the first issuers to dual list on Upstream

Dec 30, 2022 06:30 am ET

Nutriband Inc. Will Be the First Company to Dual List on Upstream

Trading scheduled to Commence on Upstream January 5, 2023

Dec 29, 2022 06:30 am ET

Nutriband Inc. to Officially Launch AI Tape brand in Q1 2023

ORLANDO, FL / ACCESSWIRE / December 29, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it has begun production of its AI Tape brand with an expected launch of the product line in Q1 2023.

Dec 14, 2022 07:00 am ET

Nutriband Approved for Dual Listing on Upstream

Trading to Commence on Upstream January 5, 2023 under Upstream Ticker Symbol NTRB; all Upstream Participants Eligible to Receive Commemorative NFT

Dec 14, 2022 06:00 am ET

Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / December 14, 2022 / RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) on The RedChip Money Report® on Bloomberg TV this Saturday, December 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Dec 05, 2022 07:00 am ET

Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3

ORLANDO, FL / ACCESSWIRE / December 5, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the third quarter ended October 31, 2022.

Dec 02, 2022 07:00 am ET

Nutriband Inc to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

ORLANDO, FL / ACCESSWIRE / December 2, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announces that Gareth Sheridan, CEO, will be presenting at the RHK Capital Disruptive Growth Conference in New York City on Monday, December 5 at 10:20 AM. Mr. Sheridan will present a corporate overview with a specific focus on the Company's AVERSA technology and market opportunity.

Dec 01, 2022 07:00 am ET

Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent

ORLANDO, FL / ACCESSWIRE / December 1, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that the Canadian Intellectual Property Office (CIPO) has granted Canadian patent No. 2,937,649, entitled "Abuse and Misuse Deterrent Transdermal Systems," with an issue date of November 1, 2022. This patent protects Nutriband's AVERSA™ transdermal abuse deterrent technology being developed to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential that are delivered with a transdermal patch.

Nov 08, 2022 07:00 am ET

Nutriband Supports Newly Published CDC Opioid Prescribing Guidelines

New guidelines reiterate need for abuse deterrent technologies and call for enabling clinicians to provide comprehensive pain management including appropriate use of opioid medications

Oct 27, 2022 07:00 am ET

Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive Agreement

ORLANDO, FL / ACCESSWIRE / October 27, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has signed an exclusive manufacturing agreement with Fleur Marché for its CBD and Botanical Patch lines. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence will act as exclusive manufacturer for the lines of products.

Oct 26, 2022 07:00 am ET

Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Present

ORLANDO, FL / ACCESSWIRE / October 26, 2022 / Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has conducted a Phase 1b clinical study for Sorrento Therapeutics, Inc. ("Sorrento") (NASDAQ:SRNE) with results to be presented at the American College of Rheumatology (ACR) Convergence 2022 Conference on November 13, 2022 as a poster abstract entitled "Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at

Oct 17, 2022 07:00 am ET

Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24

ORLANDO, FL / ACCESSWIRE / October 17, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") today announced that it has accepted an invitation as a guest speaker for the 2023 Transdermal and Microneedle Conference to be held in London on January 23 and 24. The Company's presentation will be on ‘Improving existing transdermal technologies to reduce the liability profile of abusable medications' which will discuss our AVERSA technology as a reference point. Nutriband CEO, Gareth Sheridan, will be speaking on behalf of the Com

Oct 04, 2022 07:00 am ET

Nutriband With Kindeva Drug Delivery Demonstrate Enhanced Abuse-Deterrent Characteristics for AVERSA(TM) Fentanyl

ORLANDO, FL / ACCESSWIRE / October 4, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) with Kindeva Drug Delivery have demonstrated enhanced abuse deterrence kinetics of the Company's patented lead product, Aversa™ Fentanyl, an abuse-deterrent fentanyl transdermal system, with their development and manufacturing partner, Kindeva Drug Delivery. Studies at Kindeva Drug Delivery have demonstrated that Nutriband's proprietary transdermal aversive coating can be manufactured using standard commercial transdermal manufacturing processes, which is critical to the success of th

Oct 03, 2022 07:00 am ET

Nutriband Inc. Announces Application for Dual Listing on Upstream

ORLANDO, FL / ACCESSWIRE / October 3, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") today announced that it has begun the application process to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ").

Sep 15, 2022 08:00 am ET

Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / September 15, 2022 / RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), on The RedChip Money Report® on Bloomberg TV, this Saturday, September 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Sep 08, 2022 07:00 am ET

Nutriband Inc. Reports Revenue Up 113% YoY in Q2

ORLANDO, FL / ACCESSWIRE / September 8, 2022 / Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, today announced financial and operational results for the second quarter ended July 31, 2022.

Aug 16, 2022 06:00 am ET

Nutriband Inc. Provides Update on Seven-for-Six Forward Stock Split

ORLANDO, FL / ACCESSWIRE / August 16, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that the 7:6 forward split of its common stock was effective at the opening of trading on Friday, August 12, 2022, with a record date of Monday, August 15, 2022. At the effective time of the stock split, every six (6) shares of NTRB common stock were converted into seven (7) shares of common stock, without any change in the par value per share. Fractional shares of post-split common stock will not be issued, but will be rou

Aug 10, 2022 06:00 am ET

Nutriband Inc. Details of Seven-for-Six Forward Stock Split

ORLANDO, FL / ACCESSWIRE / August 10, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") announced on July 27, 2022 that its Board of Directors had approved and declared a 7:6 forward split of its common stock with a record date of Monday, August 15, 2022 (the "Stock Split"). Each shareholder of record as of the record date will receive one (1) additional share of common stock for each six (6) shares held as of the record date.. No fractional shares of common stock will be issued in connection with the Stock Split. In

Aug 01, 2022 06:00 am ET

Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent

ORLANDO, FL / ACCESSWIRE / August 1, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for its patent application, CA 2937649, entitled "Abuse and Misuse Deterrent Transdermal Systems," that protects its AVERSA™ transdermal abuse deterrent technology. The issuance of this Canadian patent in combination with patents already issued in the United States and Mexico provides intellectual property protection for Nutriband's Aversa™ products across No

Jul 27, 2022 06:00 am ET

Nutriband Inc. Announces Seven-for-Six Forward Stock Split

ORLANDO, FL / ACCESSWIRE / July 27, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that its Board of Directors has approved and declared a 7:6 forward split of its common stock that is expected to be effective at 12:01AM on August 15 and in effect at the opening of trading on Monday August 15, 2022.

Jul 26, 2022 06:00 am ET

1.2M Shares of Nutriband Inc. to be Cancelled from Total Outstanding Shares Following Final Court Judgment in Favor of the Company

ORLANDO, FL / ACCESSWIRE / July 26, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that it has received the Final Judgment in favor of the company, effectively allowing the company to cancel 1.2M shares held by the defendants in the Court case filed in Orlando, Florida, by the Company. The shares in question equate to approximately 15% of the Company's shares now outstanding.

Jul 22, 2022 07:00 am ET

Nutriband Inc. Registers New Company Branch in Ecuador with Plans to Expand into the South American Market

ORLANDO, FL / ACCESSWIRE / July 22, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) is pleased to announce the opening of its new branch in Quito, Ecuador. The Company plans to expand its product offering to the region through product registration and contract services.

Jul 21, 2022 09:00 am ET

Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / July 21, 2022 / RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), on The RedChip Money Report® on Bloomberg TV, this Saturday, July 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Jul 15, 2022 07:00 am ET

Nutriband Inc. Successfully Obtains Court Verdict for Recovery of Shares Constituting 15% of Its Total Outstanding Shares

ORLANDO, FL / ACCESSWIRE / July 15, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that it has received a verdict in favor of the company, where the company prevailed on all issues, relating to the lawsuit the company filed to rescind the acquisition of Advanced Health Brands in 2017.

Jun 03, 2022 08:00 am ET

Nutriband Supports Update to CDC Opioid Prescribing Guidelines

New proposed guidelines reiterate need for abuse deterrent technologies and call for enabling clinicians to provide comprehensive pain management including appropriate use of opioid medications

May 27, 2022 07:50 am ET

Nutriband Inc. Interview to Air on Bloomberg U.S. on The Redchip Money Report(R)

ORLANDO, FL / ACCESSWIRE / May 27, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, contract research and development services and the contract manufacture services today announced that an interview with CEO Gareth Sheridan will air on The RedChip Money Report® on Bloomberg TV, May 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.

May 24, 2022 07:00 am ET

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 31st Emerging Growth Conference. The Emerging...

May 20, 2022 07:00 am ET

Nutriband Inc. to Present at the Emerging Growth Conference on May 25

Nutriband Inc. Invites Individual and Institutional Investors As Well as Advisors and Analysts, To Attend Its Real-Time, Interactive Presentation at the Emerging Growth Conference

May 17, 2022 06:30 am ET

Nutriband Inc. Receives Orders for $230,000 in Contract Manufacturing for First 3 Weeks of May

ORLANDO, FL / ACCESSWIRE / May 17, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today it has booked nearly a quarter of a million dollars in new in contract manufacturing orders through its wholly-owned subsidiary Pocono Pharma, extending its current run of record-breaking revenue.

May 11, 2022 07:10 am ET

Nutriband Subsidiary Active Intelligence LLC Registers with FDA as a Medical Device Manufacturer for its AI Kinesiology Tape Product

Class 1 Medical Device Registration Allows Nutriband To Explore New Product Manufacturing Opportunities Through Its Wholly Owned Subsidiary Active Intelligence LLC

Feb 16, 2022 07:30 am ET

Nutriband Inc.'s Patent, 'Abuse and Misuse Deterrent Transdermal System’ Published by the United States Patent and Trademark Office Following Recent Issuance Notice

ORLANDO, FL / ACCESSWIRE / February 16, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the United States Patent and Trademark Office (USPTO) has published its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™.

Feb 04, 2022 06:00 am ET

Nutriband Inc. To Participate in The Benzinga All Access Event on February 4

ORLANDO, FL / ACCESSWIRE / February 4, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) will be participating in the Benzinga ALL ACCESS, which will take place on February 4.

Jan 28, 2022 07:30 am ET

Nutriband Issued Full US Patent for Its Aversa(TM) Abuse Deterrent Transdermal Platform by United States Patent and Trademark Office

ORLANDO, FL / ACCESSWIRE / January 28, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced the receipt of an Issue Notification from the United States Patent and Trademark Office (USPTO) for its United States patent entitled, "Abuse and Misuse Deterrent Transdermal System," that protects its AVERSA™ transdermal abuse deterrent technology.

Jan 18, 2022 07:30 am ET

Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology

ORLANDO, FL / ACCESSWIRE / January 18, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced an expanded product development pipeline for its proprietary AVERSA™ abuse deterrent transdermal technology. The AVERSA abuse deterrent technology platform can be applied to any transdermal patch that has a risk of abuse, misuse or accidental exposure. It is based on incorporating aversive agents into the patch that do not contact the drug matrix and are not delivered to the skin.

Jan 10, 2022 07:30 am ET

Nutriband Inc. And Kindeva Drug Delivery Sign Feasibility Agreement to Develop AVERSA(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch

ORLANDO, FL / ACCESSWIRE / January 10, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced the signing of a feasibility agreement with Kindeva Drug Delivery to develop Nutriband's lead product, AVERSA™ Fentanyl, based on its proprietary AVERSA™ abuse deterrent transdermal technology and Kindeva's FDA-approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement is focused on adapting Kindeva's commercial transdermal manufacturing process to incorporate AVERSA technology.

Jan 05, 2022 07:00 am ET

Nutriband Lead Product Aversa(TM) Fentanyl May Reach Peak Annual Sales of $80-200 Million Based on Market Assessment by Leading Healthcare Consulting Firm

ORLANDO, FL / ACCESSWIRE / January 5, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products has completed the market assessment and commercialization strategy for its lead product candidate, AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system.

Dec 31, 2021 07:30 am ET

Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its "Abuse and Misuse Deterrent Transdermal System" Application

ORLANDO, FL / ACCESSWIRE / December 31, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the Korean Intellectual Property Office (KIPO) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™.

Dec 29, 2021 07:30 am ET

Nutriband Inc. Announces $1 Million Share Repurchase Authorization

ORLANDO, FL / ACCESSWIRE / December 29, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the Company had 7,773,962 shares of common stock outstanding.

Dec 21, 2021 08:30 am ET

Nutriband Inc. Initiates Plans to Offer Topical Lotion Contract Manufacturing Services

ORLANDO, FL / ACCESSWIRE / December 21, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced plans to start offering contract manufacturing services for liquid based topical, transdermal and cosmetic product's. This follows the recent certification as a cGMP facility following a full cGMP audit. The audit was conducted specifically in relation to the certification of Pharmaceutical OTC GMP, 21 CFR Part 211/210.

Dec 13, 2021 07:30 am ET

Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary

ORLANDO, FL / ACCESSWIRE / December 13, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its manufacturing subsidiary Active Intelligence, has received cGMP certification following a full cGMP audit. The audit was conducted specifically in relation to the certification of Pharmaceutical OTC GMP, 21 CFR Part 211/210.

Dec 03, 2021 07:30 am ET

Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021

ORLANDO, FL / ACCESSWIRE / December 3, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its Chief Executive Officer Gareth Sheridan and President Serguei Melnik will be joined by members of the Company's board of directors and senior management to ring the NASDAQ Stock Market Opening Bell at 9:30 a.m. EST on Friday, December 3, 2021.

Nov 16, 2021 07:30 am ET

Nutriband Inc. Initiates Commercial Development of Lead Product AVERSA(TM) Fentanyl

ORLANDO, FL / ACCESSWIRE / November 16, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, has commenced the development of its lead product candidate, AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system.

Nov 10, 2021 07:30 am ET

Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / November 10, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal, topical and coated products, today announced that an interview with CEO Gareth Sheridan will air on The RedChip Money Report® on Bloomberg TV, November 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.

Oct 22, 2021 07:30 am ET

Nutriband Inc. Receives Additional $2,062,500 from Exercise of Warrants, Increasing Total Capital from Public Offering and Nasdaq Listing to Approx. $8.7M

ORLANDO, FL / ACCESSWIRE / October 22, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, is pleased to announce the receipt of $2,062,500 in additional gross from the exercise of warrants issued in the Company's October 1, 2021 public offering of securities.

Oct 12, 2021 07:30 am ET

Nutriband Inc. Signs Exclusive Manufacturing Agreement for Diocheck(TM) Visual COVID-19 Antibody Indicator Patch

ORLANDO, FL / ACCESSWIRE / October 12, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products, today announced that it has signed an exclusive manufacturing agreement with San Diego-based Diomics for its Diocheck™ technology, a simple way for individuals to monitor for the presence of antibodies to SARS-CoV-2 (COVID-19) over an extended period of time.

Oct 05, 2021 03:35 pm ET

WestPark Capital Announces Completion of a $6.6 Million Public Offering for Nutriband Inc. (NASDAQ: NTRB) and Up-listing to the NASDAQ Capital Market

Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, announced that its common stock and warrants began trading on the Nasdaq Capital Market effective October 1, 2021.

Oct 04, 2021 07:30 am ET

Nutriband Inc.'s AVERSA(R) technology receives Notice of Allowance from United States Patent and Trademark Office (USPTO)

ORLANDO, FL / ACCESSWIRE / October 4, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application 16/707,547, entitled 'Abuse and Misuse Deterrent Transdermal Systems'. The Patent, specifically relates to the company's AVERSA® technology focused on deter

Oct 01, 2021 12:00 pm ET

Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market

ORLANDO, Fla., Oct. 1, 2021 /PRNewswire/ -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, announced that its common stock and warrants began trading on the Nasdaq Capital Market effective October 1, 2021.

Oct 01, 2021 09:45 am ET

Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market

ORLANDO, FL / ACCESSWIRE / October 1, 2021 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products focused on preventing opioid abuse, contract research and development services and the contract manufacturing of topical and transdermal products, today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market effective October 1, 2021.

Ad blocking detected

Nutriband Inc. - Warrant (OQ:NTRBW)

Business Focus: N/A